Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris

P. A. Merlini, D. Ardissino, K. A. Bauer, L. Oltrona, A. Spinola, P. Diotallevi, R. D. Rosenberg, P. M. Mannucci

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In patients with myocardial infarction, thrombolytic therapy induces a paradoxical activation of the hemostatic mechanism. In patients with unstable angina, the effect of thrombolysis on the coagulation cascade is unknown. We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A in consecutive patients with unstable angina randomized to receive placebo alone (n = 23), streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion (n = 21), or streptokinase 250,000 over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours (n = 20). All the patients received intravenous heparin for 72 hours. The plasma levels of the different markers were measured at baseline, 90 minutes, 24 hours, and 48 hours after the start of therapy. The median baseline plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A were similar in the three treatment groups. In comparison with placebo, an increase in plasma prothrombin fragment 1 + 2 and fibrinopeptide A, was observed after 90 minutes in the two groups receiving thrombolysis. After 24 and 48 hours, the prothrombin fragment 1 + 2 levels remained significantly higher only in the patients receiving the 48-hour streptokinase infusion. In patients with unstable angina, thrombolytic therapy induces an activation of the hemostatic mechanism, despite concomitant heparin administration; in those receiving a prolonged streptokinase infusion, the activation of coagulation persists for as long as the drug is administered.

Original languageEnglish
Pages (from-to)3327-3332
Number of pages6
JournalBlood
Volume86
Issue number9
Publication statusPublished - 1995

Fingerprint

Streptokinase
Unstable Angina
Hemostatics
Fibrinopeptide A
Chemical activation
Plasmas
Coagulation
Heparin
Thrombolytic Therapy
Placebos
prothrombin fragment 1
Myocardial Infarction
Pharmaceutical Preparations
prothrombin fragment 2
Therapeutics

ASJC Scopus subject areas

  • Hematology

Cite this

Merlini, P. A., Ardissino, D., Bauer, K. A., Oltrona, L., Spinola, A., Diotallevi, P., ... Mannucci, P. M. (1995). Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Blood, 86(9), 3327-3332.

Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. / Merlini, P. A.; Ardissino, D.; Bauer, K. A.; Oltrona, L.; Spinola, A.; Diotallevi, P.; Rosenberg, R. D.; Mannucci, P. M.

In: Blood, Vol. 86, No. 9, 1995, p. 3327-3332.

Research output: Contribution to journalArticle

Merlini, PA, Ardissino, D, Bauer, KA, Oltrona, L, Spinola, A, Diotallevi, P, Rosenberg, RD & Mannucci, PM 1995, 'Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris', Blood, vol. 86, no. 9, pp. 3327-3332.
Merlini PA, Ardissino D, Bauer KA, Oltrona L, Spinola A, Diotallevi P et al. Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. Blood. 1995;86(9):3327-3332.
Merlini, P. A. ; Ardissino, D. ; Bauer, K. A. ; Oltrona, L. ; Spinola, A. ; Diotallevi, P. ; Rosenberg, R. D. ; Mannucci, P. M. / Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris. In: Blood. 1995 ; Vol. 86, No. 9. pp. 3327-3332.
@article{cdba9502fcaa41b78c6f1687b107c533,
title = "Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris",
abstract = "In patients with myocardial infarction, thrombolytic therapy induces a paradoxical activation of the hemostatic mechanism. In patients with unstable angina, the effect of thrombolysis on the coagulation cascade is unknown. We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A in consecutive patients with unstable angina randomized to receive placebo alone (n = 23), streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion (n = 21), or streptokinase 250,000 over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours (n = 20). All the patients received intravenous heparin for 72 hours. The plasma levels of the different markers were measured at baseline, 90 minutes, 24 hours, and 48 hours after the start of therapy. The median baseline plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A were similar in the three treatment groups. In comparison with placebo, an increase in plasma prothrombin fragment 1 + 2 and fibrinopeptide A, was observed after 90 minutes in the two groups receiving thrombolysis. After 24 and 48 hours, the prothrombin fragment 1 + 2 levels remained significantly higher only in the patients receiving the 48-hour streptokinase infusion. In patients with unstable angina, thrombolytic therapy induces an activation of the hemostatic mechanism, despite concomitant heparin administration; in those receiving a prolonged streptokinase infusion, the activation of coagulation persists for as long as the drug is administered.",
author = "Merlini, {P. A.} and D. Ardissino and Bauer, {K. A.} and L. Oltrona and A. Spinola and P. Diotallevi and Rosenberg, {R. D.} and Mannucci, {P. M.}",
year = "1995",
language = "English",
volume = "86",
pages = "3327--3332",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris

AU - Merlini, P. A.

AU - Ardissino, D.

AU - Bauer, K. A.

AU - Oltrona, L.

AU - Spinola, A.

AU - Diotallevi, P.

AU - Rosenberg, R. D.

AU - Mannucci, P. M.

PY - 1995

Y1 - 1995

N2 - In patients with myocardial infarction, thrombolytic therapy induces a paradoxical activation of the hemostatic mechanism. In patients with unstable angina, the effect of thrombolysis on the coagulation cascade is unknown. We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A in consecutive patients with unstable angina randomized to receive placebo alone (n = 23), streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion (n = 21), or streptokinase 250,000 over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours (n = 20). All the patients received intravenous heparin for 72 hours. The plasma levels of the different markers were measured at baseline, 90 minutes, 24 hours, and 48 hours after the start of therapy. The median baseline plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A were similar in the three treatment groups. In comparison with placebo, an increase in plasma prothrombin fragment 1 + 2 and fibrinopeptide A, was observed after 90 minutes in the two groups receiving thrombolysis. After 24 and 48 hours, the prothrombin fragment 1 + 2 levels remained significantly higher only in the patients receiving the 48-hour streptokinase infusion. In patients with unstable angina, thrombolytic therapy induces an activation of the hemostatic mechanism, despite concomitant heparin administration; in those receiving a prolonged streptokinase infusion, the activation of coagulation persists for as long as the drug is administered.

AB - In patients with myocardial infarction, thrombolytic therapy induces a paradoxical activation of the hemostatic mechanism. In patients with unstable angina, the effect of thrombolysis on the coagulation cascade is unknown. We prospectively measured the plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A in consecutive patients with unstable angina randomized to receive placebo alone (n = 23), streptokinase 1,500,000 IU over 1 hour followed by a 48-hour placebo infusion (n = 21), or streptokinase 250,000 over 1 hour followed by a continuous infusion of 100,000 IU per hour over 48 hours (n = 20). All the patients received intravenous heparin for 72 hours. The plasma levels of the different markers were measured at baseline, 90 minutes, 24 hours, and 48 hours after the start of therapy. The median baseline plasma concentrations of prothrombin fragment 1 + 2 and fibrinopeptide A were similar in the three treatment groups. In comparison with placebo, an increase in plasma prothrombin fragment 1 + 2 and fibrinopeptide A, was observed after 90 minutes in the two groups receiving thrombolysis. After 24 and 48 hours, the prothrombin fragment 1 + 2 levels remained significantly higher only in the patients receiving the 48-hour streptokinase infusion. In patients with unstable angina, thrombolytic therapy induces an activation of the hemostatic mechanism, despite concomitant heparin administration; in those receiving a prolonged streptokinase infusion, the activation of coagulation persists for as long as the drug is administered.

UR - http://www.scopus.com/inward/record.url?scp=0028822453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028822453&partnerID=8YFLogxK

M3 - Article

VL - 86

SP - 3327

EP - 3332

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -